Search

Michael D Klagsbrun

from Brookline, MA
Age ~85
Get Report
Also known as:
Michael Klagsburn
Phone and address:
1265 Beacon St, Brookline, MA 02446
(617) 277-3579
Related to:
Deborah Kalin, 74Arielle K Klagsbrun, 34
Connected to:
Abigail N Klagsbrun, 58Zev Klagsbrun, 39Vatche Klahejian, 50Roseanne Klahm, 77Andy R Klahn, 40Gerard Klahn, 66Linda J Klahn, 65Matt Klahn, 54Michael M Klahn, 57Shayla Klahn, 33

Michael Klagsbrun Phones & Addresses

  • 1265 Beacon St, Brookline, MA 02446 (617) 277-3579
    • s
  • 1265 Beacon St APT 803, Brookline, MA 02446 (617) 277-3579
  • 100 Landsdowne St APT 1502, Cambridge, MA 02139
  • 22 Berwick Rd, Newton Center, MA 02459 (617) 965-5763
  • 20 Calvin Rd, Newton, MA 02460 (617) 965-5763
  • Newtonville, MA

Work

Position: Retired

Education

Degree: Graduate or professional degree

Publications

Isbn (Books And Publications)

Angiogenesis: Mechanisms and Pathobiology

View page
Author

Michael Klagsbrun

ISBN #

0879693002

The Fibroblast Growth Factor Family

View page
Author

Michael Klagsbrun

ISBN #

0897666895

The Fibroblast Growth Factor Family

View page
Author

Michael Klagsbrun

ISBN #

0897666909

Us Patents

Neuropilins And Use Thereof In Methods For Diagnosis And Prognosis Of Cancer

View page
US Patent:
6635421, Oct 21, 2003
Filed:
May 30, 2000
Appl. No.:
09/583638
Inventors:
Michael Klagsbrun - Newton MA
Shay Soker - Brookline MA
Seiji Takashima - Osaka, JP
Assignee:
Childrens Medical Center Corporation - Boston MA
International Classification:
C12Q 168
US Classification:
435 6, 435 71, 435 723, 436501
Abstract:
The present invention relates to VEGF receptors (VEGFR) and neuropilins such as VEGF R/NP-1 and NP-2 that are associated with metastatic potential of a malignant cell and their use in the diagnosis and prognosis of cancer. Preferred ones are VEGF R/NP-1 and NP-2 but any neuropilin or VEGFR, where the constituents share at least about 85% homology with either of the above VEGF R/NP-1 and NP-2 can be used. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.

Peptide Antagonists Of Vascular Endothelial Growth Factor

View page
US Patent:
6777534, Aug 17, 2004
Filed:
May 25, 2000
Appl. No.:
09/579420
Inventors:
Michael Klagsbrun - Newton MA
Shay Soker - Brookline MA
Assignee:
Childrens Medical Center Corporation - Boston MA
International Classification:
A61K 3800
US Classification:
530300, 514 2
Abstract:
The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.

Soluble Inhibitors Of Vascular Endothelial Growth Factor And Use Thereof

View page
US Patent:
7273612, Sep 25, 2007
Filed:
Mar 22, 2002
Appl. No.:
10/104610
Inventors:
Michael Klagsbrun - Newton MA, US
Shay Soker - Brookline MA, US
Michael L. Gagnon - Brighton MA, US
Assignee:
Children's Medical Center Corporation - Boston MA
International Classification:
A61K 39/00
A61K 38/17
US Classification:
4241841, 4241851
Abstract:
The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGFR/NP-1 and NP-2. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.

Antagonists Of Neuropilin Receptor Function And Use Thereof

View page
US Patent:
7335357, Feb 26, 2008
Filed:
Jul 18, 2006
Appl. No.:
11/488364
Inventors:
Michael Klagsbrun - Newton MA, US
Shay Soker - Brookline MA, US
Seiji Takashima - Osaka, JP
Assignee:
Children's Medical Center Corporation - Boston MA
International Classification:
A61K 39/395
US Classification:
4241301
Abstract:
The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.

Peptide Antagonists Of Vascular Endothelial Growth Factor

View page
US Patent:
7414027, Aug 19, 2008
Filed:
Jun 2, 2004
Appl. No.:
10/858849
Inventors:
Michael Klagsbrun - Newton MA, US
Shay Soker - Brookline MA, US
Assignee:
Childen's Medical Center Corporation - Boston MA
International Classification:
A61K 38/18
C07K 14/475
C07K 14/49
US Classification:
514 12, 514 2, 530399, 530300, 530324
Abstract:
The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.

Antagonists Of Neuropilin Receptor Function And Use Thereof

View page
US Patent:
7731959, Jun 8, 2010
Filed:
Mar 22, 2002
Appl. No.:
10/104440
Inventors:
Michael Klagsbrun - Newton MA, US
Shay Soker - Brookline MA, US
Seiji Takashima - Osaka, JP
Assignee:
Children's Medical Center Corporation - Boston MA
International Classification:
A61K 39/395
US Classification:
4241301
Abstract:
The present invention relates to antagonists of neuropilin receptor fuction and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.

Soluble Inhibitors Of Vascular Endothelial Growth Factor And Use Thereof

View page
US Patent:
7736655, Jun 15, 2010
Filed:
Aug 17, 2007
Appl. No.:
11/893633
Inventors:
Michael Klagsbrun - Newton MA, US
Shay Soker - Greensboro NC, US
Michael Gagnon - Brighton MA, US
Assignee:
Children's Medical Center Corporation - Boston MA
International Classification:
A61K 39/38
A61K 38/16
A61K 38/17
C07K 14/435
C07K 14/705
US Classification:
4241841, 4241851, 530350
Abstract:
The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGFR/NP-1 and NP-2. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.

Peptide Antagonists Of Vascular Endothelial Growth Factor And Methods Of Use Thereof

View page
US Patent:
8153585, Apr 10, 2012
Filed:
Jul 14, 2008
Appl. No.:
12/172491
Inventors:
Michael Klagsbrun - Newton MA, US
Shay Soker - Greensboro NC, US
Assignee:
Children's Medical Center Corporation - Boston MA
International Classification:
A61K 38/18
C07K 14/475
US Classification:
514 81, 530399, 514 213
Abstract:
The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment of subjects having a disease or disorder associated with VEGF activity or subjects having tumors expressing a VEGF receptor. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.
Control profile
Michael D Klagsbrun from Brookline, MA, age ~85 Get Report